Sotera Health Company (SHC) Jefferies Global Healthcare Conference 2025 summary

Business performance and outlook

• Positive outlook for 2025 with reaffirmed guidance and strong execution across teams.

• All three business segments—Sterigenics, Nelson Labs, and Nordion—are strong cash flow generators.

• Sequential and year-over-year growth seen in bioprocessing, hospital supplies, and pharma volumes.

• Margins expected to remain consistent in Sterigenics and Nordion, with margin expansion driven by Nelson Labs in 2025.

• Over $500 million in free cash flow projected for 2025–2027, with CapEx expected to decline to $110 million by 2027.

Market dynamics and supply chain

• Supply chain volatility post-COVID has stabilized, with inventory corrections largely behind.

• Labor dynamics, especially at Nelson Labs, have improved, with turnover and service rates stabilizing.

• No significant impact from tariffs or related pricing pressures; contracts remain largely fixed.

• Competitive positioning remains stable, with only minor share loss due to regulatory and community challenges.

Regulatory environment and industry structure

• New niche app regulations effective April 2026 are challenging, likely causing smaller players to exit.

• Top two industry players hold 50%-two-thirds of the market; smaller regional players are exiting or consolidating.

• Compliance investments are significant, with $200 million allocated for regulatory improvements.

• Opportunities may arise from smaller competitors’ exits, but acquisition is weighed against compliance costs.